Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830355) titled 'Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Chest Hospital
Condition:
Esophageal Squamous Cell Carcinoma
Intervention:
Drug: Anlotinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 2026
Target Sample Size: 75
To know more, visit https://clinicaltrials.gov/study/NCT07830355
Disclaimer: Cu...